Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
The Michelle trial is expected to provide high-quality evidence around the role of extended thromboprophylaxis in COVID-19 and will help guide medical decisions in clinical practice.
Description: a composite efficacy endpoint of symptomatic VTE, VTE-related death, and/or VTE detected by mandatory bilateral lower limbs venous duplex scan and computed tomography pulmonary angiogram on day 35+/-4 post-hospital discharge
Measure: Venous thromboembolism and VTE related-death Time: at day 35 +/- post hospital dischargeDescription: Incidence of major bleeding according to ISTH criteria.
Measure: Major bleeding Time: at day 35 +/- post hospital dischargeDescription: A composite of myocardial infarction, stroke, arrhythmias, heart failure, venous thromboembolism (VTE), and all-cause death.
Measure: A composite of myocardial infarction, stroke, arrhythmias, heart failure, venous thromboembolism (VTE), and all-cause death. Time: at day 35 +/- post hospital dischargeDescription: Days alive out of the hospital (DAOH) at 35 +/-4 days
Measure: Days alive out of the hospital (DAOH) at 35 +/-4 days Time: at day 35 +/- post hospital dischargeDescription: plasma level of D-dimers in ng/mL
Measure: D-dimer (Biomarker) Time: at day 35 +/- 4 post hospital dischargeDescription: plasma level of C Reactive Protein in μg/mL
Measure: C reactive protein (Biomarker) Time: at day 35 +/- 4 post hospital dischargeDescription: plasma level of PAI-1 in units/mL
Measure: PAI-1 (Biomarker) Time: at day 35 +/- 4 post hospital dischargeDescription: plasma level of TFPI in units/mL
Measure: TFPI (Biomarker) Time: at day 35 +/- 4 post hospital dischargeDescription: plasma level of Thrombomodulin in nM/mL
Measure: Thrombomodulin (Biomarker) Time: at day 35 +/- 4 post hospital dischargeDescription: plasma level of IL-6 in pg/mL
Measure: IL-6 (Biomarker) Time: at day 35 +/- 4 post hospital dischargeAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports